Gene Therapy to Target CD19 for Oncology is under clinical development by Chongqing Precision Biotech and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy to Target CD19 for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene Therapy to Target CD19 for Oncology overview
Gene therapy is under development for the treatment of relapsed and refractory B-cell non-Hodgkin lymphoma including diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL), primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL) and chronic lymphocytic leukemia (CLL). The drug candidate comprises of NK cells genetically engineered to express chimeric antigen receptor (CAR) that targets CD19.
For a complete picture of Gene Therapy to Target CD19 for Oncology’s drug-specific PTSR and LoA scores, buy the report here.